Loading clinical trials...
Loading clinical trials...
The purpose of this trial is to evaluate if it is safe to use tissue plasminogen activator (tPA) within 6 hours of stroke onset when combined with hypothermia.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of California, San Diego
Collaborators
NCT07541560 · Stroke
NCT07367100 · Ischemic Stroke
NCT07392450 · Acute Ischemic Stroke
NCT07185022 · Stroke, Cerebrovascular Disorders, and more
NCT07318714 · Chronic Ischemic Stroke
Stanford Medical Center
Palo Alto, California
University of California San Diego, Thornton Hospital
San Diego, California
Scripps Mercy Hospital
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions